XML 44 R33.htm IDEA: XBRL DOCUMENT v3.25.2
DIVESTITURES AND STRATEGIC TRANSACTIONS (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
May 09, 2025
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Loss on Assertio Therapeutics divestiture $ 8,174 $ 0 $ 8,174 $ 0  
Costs and expenses 37,257 34,743 76,977 71,528  
Cost of sales 10,677 8,889 18,463 20,066  
Selling, general and administrative expenses 16,960 $ 18,385 38,935 $ 36,909  
Assertio Therapeutics          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Cash         $ 8,200
Loss on Assertio Therapeutics divestiture 8,200   8,200    
Otrexup Decommercialization          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Costs and expenses 3,800   3,800    
Cost of sales 2,500   2,500    
Selling, general and administrative expenses $ 1,300   $ 1,300